CureVac (CVAC) has released an update.
CureVac N.V. has reported significant financial growth in the third quarter of 2024, with revenues surging to €493.9 million compared to €16.5 million in the same period last year, resulting in a net profit of €338 million. The company’s improved financial position is reflected in a substantial increase in cash and cash equivalents, growing from €402.5 million at the end of 2023 to €550.9 million by September 2024. Investors may find these results encouraging, as CureVac’s financial turnaround indicates strong operational performance and potential for future growth.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
